Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results tags : Phase 2 save search
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
ALT | $7.08 -6.47% -6.69% 1.9M
|
Commercial Services
|
| O: 1.28%
H: 5.68%
C: -0.32%
obesity momentum positive topline trial results phase 2
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
ROIV | $10.9 -0.37% -0.46% 2.8M
|
Manufacturing
|
| O: -3.29%
H: 3.34%
C: 3.06%
lupus results study phase 2
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
Published: 2023-11-22 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.44%
H: 0.63%
C: -0.05%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
ibi362 publication care chinese diabetes results phase 2
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 20:00) - prnewswire.com
LPCN | $4.44 -7.5% -6.43% 66K
|
Health Technology
|
| O: -2.52%
H: 6.27%
C: -0.92%
meeting liver presentation results phase 2
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
Published: 2023-11-07 (Crawled : 14:00) - biospace.com/
PXMD | $0.692 -3.35% -2.24% 250K
|
Health Technology
|
| O: 93.77%
H: 73.6%
C: -23.86%
publication results study phase 2
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
CLDX | $37.02 -1.99% -2.15% 390K
|
Health Technology
|
| O: 26.94%
H: 1.73%
C: -11.01%
urticaria positive topline therapeutics results study phase 2
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
Published: 2023-11-05 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
MLTX | $42.43 -1.9% -1.88% 270K
|
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
nanobody active results phase 2
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
Published: 2023-10-24 (Crawled : 23:00) - globenewswire.com
GRFS | $6.39 -1.39% -1.25% 960K
|
Health Technology
|
| O: -4.21%
H: 1.1%
C: 0.26%
biotech vaccine alzheimer’s positive results study phase 2
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ADXS | $0.54 12.48% 270
|
Health Technology
|
| O: 0.0%
H: 5.56%
C: 0.0%
al102 congress tumors pharmaceuticals trial results phase 2
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
Published: 2023-10-22 (Crawled : 08:20) - globenewswire.com
OLMA | $10.15 1.5% 1.48% 550K
|
Health Technology
| Email alert
Add to watchlist
positive results study phase 2
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
Published: 2023-10-19 (Crawled : 20:00) - globenewswire.com
AEON | $4.01 -6.74% 0.0% 38K
|
|
| O: 1.36%
H: 2.02%
C: -3.36%
abp-450 treatment biopharma topline trial migraine results phase 2
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
Published: 2023-10-17 (Crawled : 11:00) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -62.87%
H: 55.26%
C: 5.26%
edp2939 psoriasis results study phase 2
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
Published: 2023-10-16 (Crawled : 11:00) - globenewswire.com
OLMA | $10.15 1.5% 1.48% 550K
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: -16.75%
congress results phase 2
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Published: 2023-09-28 (Crawled : 15:00) - biospace.com/
EDSA | $4.31 -3.47% -3.84% 5.1K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -9.07%
drug candidate biotech results phase 2
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions
Published: 2023-09-10 (Crawled : 12:20) - globenewswire.com
MLYS 4 | $11.36 -0.61% -1.15% 54K
|
| Email alert
Add to watchlist
sessions hypertension trial therapeutics results phase 2
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Published: 2023-09-07 (Crawled : 05:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.55%
candidate disease report vaccine positive valneva results phase 2
Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions
Published: 2023-09-05 (Crawled : 20:00) - globenewswire.com
MLYS 4 | $11.36 -0.61% -1.15% 54K
|
|
| O: -0.08%
H: 1.23%
C: -0.57%
presentation sessions hypertension trial therapeutics results phase 2
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
ADVM | News | $10.19 -7.36% -7.95% 400K
|
Health Technology
|
| O: 4.37%
H: 3.72%
C: -1.05%
trial financial results phase 2
Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
Published: 2023-08-09 (Crawled : 12:00) - globenewswire.com
PALI | $6.35 7.26% 7.36% 450K
|
Manufacturing
|
| O: -69.07%
H: 22.78%
C: 20.62%
lb1148 topline results study phase 2
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
Published: 2023-08-03 (Crawled : 13:00) - biospace.com/
VRTX | $400.76 -1.03% -1.06% 810K
|
Health Technology
|
| O: -0.95%
H: 0.52%
C: -2.05%
vx-548 positive publication results phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.